ArticleFrontiers in oncology2025
Anesthesia is a potent determinant of ultra-high dose rate sparing in the murine total abdominal irradiation model.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- FLASH radiotherapy as an emerging paradigm in radioimmunotherapy: biological rationale, preclinical evidence, and translational roadmap.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Radiation therapy is a mainstay of treatment for numerous gastrointestinal (GI) malignancies, where our ability to deliver dose to tumors is limited by acute GI toxicity. Ultra-high dose-rate (UHDR) 'FLASH' irradiation can spare normal tissue, yet its dependence on physiological variables remains incompletely defined. Methods: We compared FLASH and conventional dose-rate (CDR) 9 MeV electron total abdominal irradiation (TAI) in C57BL/6 mice anesthetized with either intraperitoneal ketamine/xylazine or inhaled isoflurane in room air, deliberately omitting supplemental oxygen. Single doses of 14 or 16 Gy were delivered, and normal-tissue injury was quantified by time-to-25% body-weight loss. Results: At 14 Gy, UHDR under K/X produced a marked survival advantage: by day 14, 80% of animals had not reached the weight-loss endpoint versus 40% after CDR K/X; no FLASH benefit was discernible with ISO anesthesia. Raising the dose to 16 Gy accentuated these trends; 40% of UHDR K/X mice were still below the endpoint at study termination, whereas all CDR K/X mice met it by day 7. Again, ISO abolished sparing at both dose rates. To probe mechanism, intraperitoneal oxygen tension was measured with an optical reporter in six mice. ISO anesthesia yielded significantly higher pO2 (62 ± 4 mmHg) than K/X (26 ± 10mmHg), a 2.5-fold difference. Discussion: These findings identify anesthetic-dependent oxygenation as a reproducible confounder in pre-clinical FLASH studies: elevated pO2 under ISO negates abdominal sparing, whereas K/X preserves it across two clinically relevant doses. Rigorous control and reporting of factors that alter tissue oxygenation are therefore essential when designing experiments and, ultimately, translating FLASH radiotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.